Prosensa Therapeutics wanted to demonstrate its committed focus to make a difference to patients through its strategy to take its innovative drugs based on its exon skipping technology all the way through clinical development and to market.
This required the company to raise sufficient finance and seek a regulatory path to develop its lead therapeutics for the treatment of the rare and life shortening disease Duchenne muscular dystrophy (DMD).
Alongside an ongoing programme of engagement with key audiences, including media, investors and patient groups, we developed an active strategy of award entries, to demonstrate the progress being made by Prosensa’s management towards its ultimate goal of launching its first DMD therapy.
We identified awards appropriate to its progress in innovation, company development, pipeline development and financing.
We crafted award entries and, where successful, promoted the achievement through press releases and social media.
There have been a large number of award recognitions:
2011 – EuropaBio Most Innovative European SME Award
2012 – Mediscience Emerging Star Award
2012 – Fierce Biotech Fierce15
2013 – ROAR Best SME Biotech Pipeline
2014 – Scrip Biotech Company of the Year
2015 – BioCapital Europe Company of the Year